These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29190879)

  • 41. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
    Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
    Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A recombinant protein containing highly conserved hemagglutinin residues 81-122 of influenza H5N1 induces strong humoral and mucosal immune responses.
    Li Y; Du L; Qiu H; Zhao G; Wang L; Zhou Y; Jiang S; Gao J
    Biosci Trends; 2013 Jun; 7(3):129-37. PubMed ID: 23836036
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A highly immunogenic vaccine against A/H7N9 influenza virus.
    Cao W; Liepkalns JS; Hassan AO; Kamal RP; Hofstetter AR; Amoah S; Kim JH; Reber AJ; Stevens J; Katz JM; Gangappa S; York IA; Mittal SK; Sambhara S
    Vaccine; 2016 Feb; 34(6):744-9. PubMed ID: 26765287
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
    Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
    J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.
    Wack A; Baudner BC; Hilbert AK; Manini I; Nuti S; Tavarini S; Scheffczik H; Ugozzoli M; Singh M; Kazzaz J; Montomoli E; Del Giudice G; Rappuoli R; O'Hagan DT
    Vaccine; 2008 Jan; 26(4):552-61. PubMed ID: 18162266
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
    Atmar RL; Keitel WA; Patel SM; Katz JM; She D; El Sahly H; Pompey J; Cate TR; Couch RB
    Clin Infect Dis; 2006 Nov; 43(9):1135-42. PubMed ID: 17029131
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intranasal Immunization with Pressure Inactivated Avian Influenza Elicits Cellular and Humoral Responses in Mice.
    Barroso SP; Nico D; Nascimento D; Santos AC; Couceiro JN; Bozza FA; Ferreira AM; Ferreira DF; Palatnik-de-Sousa CB; Souza TM; Gomes AM; Silva JL; Oliveira AC
    PLoS One; 2015; 10(6):e0128785. PubMed ID: 26056825
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Generation and Characterization of Live Attenuated Influenza A(H7N9) Candidate Vaccine Virus Based on Russian Donor of Attenuation.
    Shcherbik S; Pearce N; Balish A; Jones J; Thor S; Davis CT; Pearce M; Tumpey T; Cureton D; Chen LM; Villanueva J; Bousse TL
    PLoS One; 2015; 10(9):e0138951. PubMed ID: 26405798
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.
    Quan FS; Huang C; Compans RW; Kang SM
    J Virol; 2007 Apr; 81(7):3514-24. PubMed ID: 17251294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 virus vaccine with or without aluminum adjuvant in mice.
    Xu W; Zheng M; Zhou F; Chen Z
    Clin Vaccine Immunol; 2015 Mar; 22(3):327-35. PubMed ID: 25589552
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(1):244-51. PubMed ID: 15802970
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune Enhancement by the Tetra-Peptide Hydrogel as a Promising Adjuvant for an H7N9 Vaccine against Highly Pathogenic H7N9 Virus.
    Wu X; Tang S; Wang Z; Ma X; Zhang L; Zhang F; Xiao L; Zhao S; Li Q; Wang Y; Wang Q; Chen K
    Vaccines (Basel); 2022 Jan; 10(1):. PubMed ID: 35062791
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Humoral and Cellular Immunogenicity Induced by Avian Influenza A (H7N9) DNA Vaccine in Mice.
    Choi EJ; Lee HS; Noh JY; Song JY; Cheong HJ; Shin OS; Lee H; Jeong M; Kim WJ
    Infect Chemother; 2017 Jun; 49(2):117-122. PubMed ID: 28681576
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of mOMV adjuvant efficacy in the pathogenic H1N1 influenza virus vaccine.
    Lee BJ; Kwon HI; Kim EH; Park SJ; Lee SH; Choi YK; Kim SH
    Clin Exp Vaccine Res; 2014 Jul; 3(2):194-201. PubMed ID: 25003093
    [TBL] [Abstract][Full Text] [Related]  

  • 60. H7N9 influenza split vaccine with SWE oil-in-water adjuvant greatly enhances cross-reactive humoral immunity and protection against severe pneumonia in ferrets.
    de Jonge J; van Dijken H; de Heij F; Spijkers S; Mouthaan J; de Jong R; Roholl P; Adami EA; Akamatsu MA; Ho PL; Brunner L; Collin N; Friede M; Ferreira JA; Luytjes W
    NPJ Vaccines; 2020; 5(1):38. PubMed ID: 32411401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.